Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors

Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors

In order to improve the positional adaptability of our previously reported naphthyl diaryltriazines (NP-DATAs), synthesis of a series of novel biphenyl-substituted diaryltriazines (BP-DATAs) with a flexible side chain attached at the C-6 position is presented. These compounds exhibited excellent pot...

Full description

Bibliographic Details
Main Authors:	Kaijun Jin, Minjie Liu, Chunlin Zhuang, Erik De Clercq, Christophe Pannecouque, Ge Meng, Fener Chen
Format:	Article
Language:	English
Published:	Elsevier 2020-02-01
Series:	Acta Pharmaceutica Sinica B
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383519301832

Similar Items

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
by: Chunlin Zhuang, et al.
Published: (2020-06-01)

Discovery of Biphenyl-Substituted Diarylpyrimidines as New Non-Nucleoside HIV-1 Reverse Transcripttase Inhibitors
by: Kaijun Jin, et al.
Published: (2017-10-01)

Designing Novel Hydrazinecarbothioamides as Potential HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Hong Yin, et al.
Published: (2017-10-01)

Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs
by: Ting-Ting Li, et al.
Published: (2020-03-01)

Intracellular phosphorylation of nucleoside reverse transcriptase inhibitors
by: Sales, Sean Douglas
Published: (2000)

Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
by: N. S. Shastina, et al.
Published: (2011-04-01)

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
by: Lewi Paul, et al.
Published: (2011-10-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Valeria Famiglini, et al.
Published: (2016-02-01)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
by: Pei-Ying Wu, et al.
Published: (2017-01-01)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020-06-01)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
by: George W Rutherford, et al.
Published: (2016-01-01)

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy
by: Yuan Lei, et al.
Published: (2020-02-01)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.
by: Meytal Galilee, et al.
Published: (2018-01-01)

Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors—In Silico Activity Prediction
by: Aleksandra Dąbrowska, et al.
Published: (2018-10-01)

Kinetic analysis of HIV-1 reverse transcriptase in the presence of non-nucleoside inhibitors
by: Wang, Louise Zhiying
Published: (2008)

The design and synthesis of novel HIV-1 non-nucleoside reverse transcriptase inhibitors
by: Pribut, Nicole
Published: (2015)

The rational design and synthesis of novel HIV non-nucleoside reverse transcriptase inhibitors
by: Muller, Ronel
Published: (2013)

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
by: A. V. Kravchenko, et al.
Published: (2018-07-01)

Synthesis and anti-human immunodeficiency virus activity of substituted (-difluorophenyl)-linked-pyrimidines as potent non‐nucleoside reverse transcriptase inhibitors
by: Lucie Čechová, et al.
Published: (2019-02-01)

Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition.
by: R Brad Jones, et al.
Published: (2008-01-01)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
by: Peter V. Coveney, et al.
Published: (2012-07-01)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
by: Nicolas Sluis-Cremer, et al.
Published: (2013-11-01)

Exploring QSAR of Non-Nucleoside Reverse Transcriptase Inhibitors by Neural Networks: TIBO Derivatives
by: Driss Cherqaoui, et al.
Published: (2004-01-01)

Mitochondrial toxicity of nucleoside reverse transcriptase inhibitors in a rat phaeochromocytoma cell line
by: Clarke, Anna B.
Published: (2006)

Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions
by: Ming-Tain Lai, et al.
Published: (2016-09-01)

Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV.
by: Davide De Francesco, et al.
Published: (2021-01-01)

Exploring QSAR of non-nucleoside reverse transcriptase inhibitors by artificial neural networks: HEPT derivatives
by: Mohamed Zahouily, et al.
Published: (2007-09-01)

Novel Thiazolidin-4-ones as Potential Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
by: Anthi Petrou, et al.
Published: (2019-10-01)

3D QSAR Studies of DAMNI Analogs as Possible Non-nucleoside Reverse Transcriptase Inhibitors
by: S. Ganguly, et al.
Published: (2008-01-01)

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ARE ANTI-INFLAMMATORY AND TARGET DRY AGE-RELATED MACULAR DEGENERATION
by: Fowler, Benjamin J
Published: (2014)

Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
by: Bienczak, Andrzej Marek
Published: (2017)

Modeling of cytotoxicity on some non- nucleoside reverse transcriptase inhibitors of HIV-1: role of physicochemical parameters
by: B.K. Tiwari, et al.
Published: (2006-02-01)

Nelfinavir and Non-Nucleoside Reverse Transcriptase Inhibitor-Based Salvage Regimes in Heavily Hiv Pretreated Patients
by: Jean-Guy Baril, et al.
Published: (2003-01-01)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
by: Mastan SK, et al.
Published: (2009-10-01)

Efficacy of nucleoside reverse transcriptase inhibitors on a HIV-1 infected human brain aggregate model
by: Kandanearatchi, Apsara Lakmini
Published: (2003)

Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-β induced retinal pigmented epithelium degeneration
by: Siddharth Narendran, et al.
Published: (2021-04-01)

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
by: Alexandra U Scherrer, et al.
Published: (2012-01-01)

Genotypic and phenotypic characteristics of HIV-1 clade C resistant variants selected in vitro against nucleoside and non-nucleoside inhibitors of reverse transcriptase
by: Loemba, Hugues D.
Published: (2001)

Nucleoside reverse transcriptase inhibitors (NRTIs) induce proinflammatory cytokines in the CNS via Wnt5a signaling
by: Ting Wu, et al.
Published: (2017-06-01)

Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations
by: Van Houtte Margriet, et al.
Published: (2011-10-01)